Patents by Inventor Pavol Zlatoidský

Pavol Zlatoidský has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic peptide ligands specific for TSLP
    Patent number: 11866518
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of thymic stromal lymphopoietin (TSLP). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder mediated by TSLP.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: January 9, 2024
    Assignee: BicycleTx Limited
    Inventors: Frank Narjes, Tor Svensson, Pavol Zlatoidsky, Lotta Hidestal, Liuhong Chen, Michael Skynner, Sophie Watcham
  • BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP
    Publication number: 20220363718
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of thymic stromal lymphopoietin (TSLP). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder mediated by TSLP.
    Type: Application
    Filed: April 6, 2021
    Publication date: November 17, 2022
    Inventors: Frank NARJES, Tor SVENSSON, Pavol ZLATOIDSKY, Lotta HIDESTAL, Liuhong CHEN, Michael SKYNNER, Sophie WATCHAM
  • INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA
    Publication number: 20210047312
    Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3K?) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: November 4, 2020
    Publication date: February 18, 2021
    Applicant: AstraZeneca AB
    Inventors: Mickael MOGEMARK, Nils PEMBERTON, Jens PETERSEN, Matthew PERRY, Konstantinos KARABELAS, Pavol ZLATOIDSKY, Rhona COX, Christian TYRCHAN
  • Inhibitors of phosphatidylinositol 3-kinase gamma
    Patent number: 10858355
    Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3K?) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: December 8, 2020
    Assignee: AstraZeneca AB
    Inventors: Mickael Mogemark, Nils Pemberton, Jens Petersen, Matthew Perry, Konstantinos Karabelas, Pavol Zlatoidsky, Rhona Cox, Christian Tyrchan
  • NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA
    Publication number: 20200299289
    Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (P13K?) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: March 9, 2017
    Publication date: September 24, 2020
    Applicant: AstraZeneca AB
    Inventors: Mickael MOGEMARK, Nils PEMBERTON, Jens PETERSEN, Matthew PERRY, Konstantinos KARABELAS, Pavol ZLATOIDSKY, Rhona COX, Christian TYRCHAN
  • Metalloproteinase inhibitors
    Patent number: 8153673
    Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: April 10, 2012
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Metalloproteinase Inhibitors
    Publication number: 20110003853
    Abstract: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Application
    Filed: July 6, 2010
    Publication date: January 6, 2011
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenchöld, Pavol Zlatoidsky
  • Metalloproteinase Inhibitors
    Publication number: 20100273849
    Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Application
    Filed: January 26, 2010
    Publication date: October 28, 2010
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenchöld, Pavol Zlatoidsky
  • Novel Hydantoin Derivatives as Metalloproteinase Inhibitors
    Publication number: 20100256166
    Abstract: The invention provides compounds of formula (I): wherein R1, R2, A, A1 and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.
    Type: Application
    Filed: February 1, 2010
    Publication date: October 7, 2010
    Inventors: Balint Gabos, Michael Lundkvist, Magnus Munck Af Rosenschold, Igor Shamovsky, Pavol Zlatoidsky
  • Metalloproteinase inhibitors
    Patent number: 7754750
    Abstract: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: July 13, 2010
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Hydantoin derivatives as metalloproteinase inhibitors
    Patent number: 7700604
    Abstract: The invention provides compounds of formula (I): wherein R1, R2, A, A1 and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: April 20, 2010
    Assignee: AstraZeneca AB
    Inventors: Balint Gabos, Michael Lundkvist, Magnus Munck Af Rosenschold, Igor Shamovsky, Pavol Zlatoidsky
  • Metalloproteinase inhibitors
    Patent number: 7666892
    Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: February 23, 2010
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Hydantoin derivatives as metalloproteinase inhibitors
    Patent number: 7655664
    Abstract: The invention provides compounds of formula (I): wherein R1, R2, A, A1 and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: February 2, 2010
    Assignee: AstraZeneca AB
    Inventors: Balint Gabos, Michael Lundkvist, Magnus Munck Af Rosenschold, Igor Shamovsky, Pavol Zlatoidsky
  • Metalloproteinase inhibitors
    Patent number: 7625934
    Abstract: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: December 1, 2009
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Metalloproteinase Inhibitors
    Publication number: 20080306065
    Abstract: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Application
    Filed: May 6, 2008
    Publication date: December 11, 2008
    Inventors: Anders Eriksson, Matti Lepisto, Michael Lundkvist, Magnus Munck Af Rosenschold, Pavol Zlatoidsky
  • Novel Hydantoin Derivatives as Metalloproteinase Inhibitors
    Publication number: 20080293743
    Abstract: The invention provides compounds of formula (I): wherein R1, R2, A, A1 and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.
    Type: Application
    Filed: December 14, 2005
    Publication date: November 27, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Balint Gabos, Michael Lundkvist, Magnus Munck Af Rosenschold, Igor Shamovsky, Pavol Zlatoidsky
  • Metalloproteinase Inhibitors
    Publication number: 20080262045
    Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Application
    Filed: May 5, 2008
    Publication date: October 23, 2008
    Inventors: Anders Eriksson, Matti Lepisto, Michael Lundkvist, Magnus Munck Af Rosenschold, Pavol Zlatoidsky
  • Metalloproteinase inhibitors
    Patent number: 7427631
    Abstract: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: September 23, 2008
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Metalloproteinase Inhibitors
    Publication number: 20080171882
    Abstract: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Application
    Filed: October 30, 2007
    Publication date: July 17, 2008
    Inventors: Anders Eriksson, Matti Lepisto, Michael Lundkvist, Magnus Munck Af Rosenchold, Pavol Zlatoidsky
  • Metalloproteinase inhibitors
    Patent number: 7368465
    Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: May 6, 2008
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky